Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 2
2006 1
2007 3
2008 2
2009 2
2010 5
2011 6
2012 6
2013 11
2014 5
2015 9
2016 7
2017 5
2018 10
2019 6
2020 5
2021 3
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Evaluating a Remotely Delivered Cardio-Oncology Rehabilitation Intervention for Patients With Breast Cancer (REMOTE-COR-B): Protocol for a Single-Arm Feasibility Trial.
Short CE, Rawstorn JC, Jones TL, Edbrooke L, Hayes SC, Maddison R, Nightingale S, Ismail H, De Boer R, Hegi-Johnson F, Sverdlov AL, Bell R, Halligan I, Denehy L. Short CE, et al. Among authors: de boer r. JMIR Res Protoc. 2024 Apr 5;13:e53301. doi: 10.2196/53301. JMIR Res Protoc. 2024. PMID: 38578682 Free PMC article.
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Liu SV, Mok TSK, Nabet BY, Mansfield AS, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair MJ, Garassino MC, Gay CM, Heymach JV, Byers LA, Lam S, Cardona A, Morris S, Adler L, Shames DS, Reck M. Liu SV, et al. Among authors: de boer r. Lung Cancer. 2023 Dec;186:107418. doi: 10.1016/j.lungcan.2023.107418. Epub 2023 Oct 31. Lung Cancer. 2023. PMID: 37931445 Free article. Clinical Trial.
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Loft M, Lok SW, De Boer R, Malik L, Greenberg S, Yeo B, Anton A, Nottage M, Wong V, Nott L, Collins IM, Torres J, Barnett F, Lombard JM, Gibbs P, Gately L. Loft M, et al. Among authors: de boer r. Breast Cancer Res Treat. 2023 Feb;198(1):67-74. doi: 10.1007/s10549-022-06856-1. Epub 2023 Jan 9. Breast Cancer Res Treat. 2023. PMID: 36624321
Measurement of 19F(p, γ)20Ne reaction suggests CNO breakout in first stars.
Zhang L, He J, deBoer RJ, Wiescher M, Heger A, Kahl D, Su J, Odell D, Chen Y, Li X, Wang J, Zhang L, Cao F, Zhang H, Zhang Z, Jiang X, Wang L, Li Z, Song L, Zhao H, Sun L, Wu Q, Li J, Cui B, Chen L, Ma R, Li E, Lian G, Sheng Y, Li Z, Guo B, Zhou X, Zhang Y, Xu H, Cheng J, Liu W. Zhang L, et al. Nature. 2022 Oct;610(7933):656-660. doi: 10.1038/s41586-022-05230-x. Epub 2022 Oct 26. Nature. 2022. PMID: 36289385
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.
Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, Nottage M, Tafreshi A, Tsoi D, Uccellini A, Hong W, Gibbs P, Lok SW. Wong V, et al. Among authors: de boer r. Clin Breast Cancer. 2022 Dec;22(8):792-800. doi: 10.1016/j.clbc.2022.08.011. Epub 2022 Aug 30. Clin Breast Cancer. 2022. PMID: 36151018
Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA).
Lok SW, De Boer R, Baron-Hay S, Button P, Devitt B, Forster BC, Fox P, Harold M, Ketheeswaran S, Kichenadasse G, Kiely BE, Marx G, Nott L, Pellegrini L, Tafreshi A, Gibbs P. Lok SW, et al. Among authors: de boer r. Int J Cancer. 2023 Jan 15;152(2):267-275. doi: 10.1002/ijc.34245. Epub 2022 Aug 25. Int J Cancer. 2023. PMID: 36005450 Free article.
Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study.
Tung I, Moldovan C, Wong V, De Boer R, Yeo B, Malik L, Greenberg S, Anton A, Nott L, Barnett F, Collins IM, Lombard J, Nottage M, Sahu A, Torres J, Gibbs P, Lok SW. Tung I, et al. Among authors: de boer r. Clin Breast Cancer. 2022 Oct;22(7):e764-e772. doi: 10.1016/j.clbc.2022.07.005. Epub 2022 Jul 14. Clin Breast Cancer. 2022. PMID: 35941066
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV. Reck M, et al. Among authors: de boer r. J Thorac Oncol. 2022 Sep;17(9):1122-1129. doi: 10.1016/j.jtho.2022.05.016. Epub 2022 Jun 25. J Thorac Oncol. 2022. PMID: 35764236 Free article. Clinical Trial.
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O'Shaughnessy J. Fasching PA, et al. Among authors: de boer r. Cancer Manag Res. 2021 Nov 1;13:8179-8189. doi: 10.2147/CMAR.S325043. eCollection 2021. Cancer Manag Res. 2021. PMID: 34754238 Free PMC article.
90 results